Uni Eropa - Esti - EMA (European Medicines Agency)

sanofi winthrop industrie - dronedaroon - kodade fibrillatsioon - südame teraapia - multaq on näidustatud siinusurma säilitamiseks pärast edukat kardioversiooni täiskasvanud kliiniliselt stabiilsetel patsientidel, kellel on paroksüsmaalne või püsiv kodade virvendusarütmia (af).. tänu oma ohutusprofiilile tuleb multaq'i määrata ainult pärast alternatiivsete ravivõimaluste kaalumist. multaq ei tohi anda patsientidele, kellel on vasaku vatsakese süstoolse düsfunktsiooni või patsientidele, kellel on praeguse või eelmise episoodi südamepuudulikkus.

Uni Eropa - Esti - EMA (European Medicines Agency)

sanofi winthrop industrie - klopidogreeli vesiniksulfaat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombootilised ained - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. ennetamine atherothrombotic ja trombembooliliste sündmuste kodade fibrillationin täiskasvanud patsientidel, kellel on kodade virvendus, kes on vähemalt üks riskifaktor veresoonkonna sündmused, ei sobi ravi koos vitamiin-k antagonistid ja kes on vähese verejooksu riski, clopidogrel on näidustatud kombinatsioonis asa ennetamise atherothrombotic ja trombembooliliste sündmuste, sealhulgas insult.

Estonia - Esti - Ravimiamet

sanofi winthrop industrie - levofloksatsiin - õhukese polümeerikattega tablett - 500mg 14tk; 500mg 10tk; 500mg 500tk; 500mg 5tk; 500mg 1tk; 500mg 50tk; 500mg 200tk; 500mg 7tk

Estonia - Esti - Ravimiamet

sanofi winthrop industrie - levofloksatsiin - õhukese polümeerikattega tablett - 250mg 10tk; 250mg 1tk; 250mg 7tk; 250mg 5tk; 250mg 200tk; 250mg 3tk

Uni Eropa - Esti - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mitu müeloomit - antineoplastilised ained - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Estonia - Esti - Ravimiamet

zentiva k.s. - alendroonhape+kolekaltsiferool - tablett - 70mg+5600rÜ 12tk; 70mg+5600rÜ 2tk

Estonia - Esti - Ravimiamet

zentiva k.s. - alendroonhape+kolekaltsiferool - tablett - 70mg+2800rÜ 4tk; 70mg+2800rÜ 12tk

Estonia - Esti - Ravimiamet

septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,005mg 1ml 1.7ml 400tk; 40mg+0,005mg 1ml 1.7ml 200tk; 40mg+0,005mg 1ml 1.7ml 50tk

Estonia - Esti - Ravimiamet

septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,01mg 1ml 1.7ml 50tk

Uni Eropa - Esti - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hüperkolesteroleemia - lipiidi modifitseerivad ained - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).